NCT07759024

Brief Summary

Cesarean delivery in critically ill pregnant women, especially outside the operating room, is a rare but high-risk situation for both mother and fetus. These patients often suffer from severe conditions (hypertensive disorders, hemorrhage, respiratory failure, infection, or trauma) and may require emergency cesarean in the ICU, emergency department, or prehospital setting. They frequently need advanced organ support and face higher rates of complications, prolonged ICU stay, and maternal mortality. Non-OR environments also create challenges in sterility, coordination, and management. Neonatal outcomes are often impaired by iatrogenic prematurity. Current evidence is limited. A large nationwide registry is needed to better describe outcomes and support future protocols and recommendations.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
15mo left

Started Oct 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 29, 2026

Completed
13 days until next milestone

First Posted

Study publicly available on registry

August 11, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2026

Expected
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

August 11, 2026

Status Verified

August 1, 2026

Enrollment Period

1.2 years

First QC Date

July 29, 2026

Last Update Submit

August 10, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Maternal mortality

    Maternal mortality, defined according to the ICD-10 classification as any death occurring during pregnancy or within 42 days after the end of pregnancy from any cause related to or aggravated by the pregnancy or its management, excluding accidental or incidental causes. The end of pregnancy will be defined as the date of cesarean delivery or vaginal delivery. Women dying before delivery will be considered as maternal deaths occurring during pregnancy.

    during pregnancy or within 42 days after the end of pregnancy

Secondary Outcomes (6)

  • Incidence

    up to delivery

  • Description of the organisational arrangements for performing caesarean sections outside the operating room

    up to delivery

  • •Maternal adverse outcomes (observed or not)

    peri and post delivery

  • Neonatal mortality

    Day 28

  • Neonatal adverse outcomes

    during hospitalization

  • +1 more secondary outcomes

Study Arms (3)

Study group:

• Study group: cesarean delivery performed outside the operating room (ICU, high-dependency unit, emergency department, or prehospital setting).

Comparison group

• Comparison group: women admitted to critical care without cesarean delivery outside the operating room, including: * cesarean delivery performed in the operating room; * women who did not undergo cesarean delivery.

Descriptive subgroup:

• Descriptive subgroup: women who died during pregnancy (≥22 weeks of gestation) without undergoing cesarean delivery.

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant women (≥22 weeks of gestation) admitted to an intensive care unit or high-dependency unit.
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Pregnant women (≥22 weeks of gestation) admitted to an intensive care unit or high-dependency unit.

You may qualify if:

  • Women aged ≥18 years.
  • Pregnancy ≥22 weeks of gestation.
  • Admission (or planned admission) to a critical care unit.

You may not qualify if:

  • Age \<18 years.
  • Objection to the use of medical data.
  • Patients under legal protection (guardianship or similar legal measures).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Emilie RAIMOND, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 29, 2026

First Posted

August 11, 2026

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

August 11, 2026

Record last verified: 2026-08